ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:

Dictionar de medicamente online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Dictionar medical online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Puteti trimite articole cu tema medicala la
adresa de email

Solutie antistress!
Construieste poduri :)

Joc, Construieste podul, Cargo Bridge

Prinde pisica neagra :)
Prinde pisica neagra- Chat Noir - Flash game

ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion On ENHANCE Trial

ReachMD, an innovative multi-channel platform for medical professionals, will air on XM Satellite Radio Channel 157 and simulcast via ReachMD Online at http://www.reachmd.com, a candid medical discussion on the much talked-about ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) Trial. Two of the nation's leading experts in Cardiology will share their insights over the only national broadcast network, created specifically for medical professionals.

Moderated by Dr. Matthew Sorrentino, associate professor of medicine at University of Chicago, this ReachMD Special Report will feature Dr. Steven Nissen, chairman of cardiology at the Cleveland Clinic, and Dr. Roger Blumenthal, head of preventive cardiology at Johns Hopkins University, who will for the first time openly debate among peers what this controversy means to the practicing physician and their patients.

The ENHANCE trial is a multinational, randomized, double-blind, trial that examines the effects of the highest approved dose of VYTORIN/INEGY versus the highest approved dose of simvastatin 80 mg alone in patients with Heterozygous Familial Hypercholesterolemia (HeFH). The study was made public by Merck/Schering-Plough Pharmaceuticals.

"The debate around the clinical study on cholesterol drugs has received heavy exposure in a short amount of time," said Gary Epstein, CEO of ReachMD. "However, there hasn't been a true, peer-to-peer discussion between the leading cardiologists in this type of setting. Our Special Report offers physicians an innovative platform to hear from medical experts in an environment created specifically for medical professionals."

The ReachMD Special Report will be easily accessible to a broad medical community through multiple channels throughout the day:

-- Satellite Radio - XM Channel 157, beginning at 1:30 p.m. EST

-- Online Simulcast - http://www.reachmd.com, beginning at 1:30 p.m. EST

-- Downloadable Podcast - http://www.reachmd.com available at 6:00 a.m. EST About ReachMD

ReachMD, headquartered in Highland Park, Illinois, is a leading provider of advanced healthcare information and education for medical professionals. ReachMD XM 157 remains committed to its mission of delivering highly relevant education, information and communication to medical professionals. The ReachMD XM channel is a new and innovative media vehicle that continues to deliver on this mission. The company's proprietary technology provides the most up-to- date healthcare information in the field through a multi-channel platform that includes satellite radio and online programs accessed through any XM radio, digital media device or PC. Through this platform, healthcare professionals receive the latest information in best practices and new advances in treatment, delivered through convenient and accessible ways. For more information, visit http://www.reachmd.com.

ReachMD
http://www.reachmd.com





Prima ReachMD emisiunilor sale de-a-Tip-Peer-Peer Medic de discutii Pe de încercare de a spori - ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion On ENHANCE Trial - articole medicale engleza - startsanatate